[go: up one dir, main page]

NO20041758L - Crystalline sodium salt of telmiseartan and its use as angiotensin antagonist - Google Patents

Crystalline sodium salt of telmiseartan and its use as angiotensin antagonist

Info

Publication number
NO20041758L
NO20041758L NO20041758A NO20041758A NO20041758L NO 20041758 L NO20041758 L NO 20041758L NO 20041758 A NO20041758 A NO 20041758A NO 20041758 A NO20041758 A NO 20041758A NO 20041758 L NO20041758 L NO 20041758L
Authority
NO
Norway
Prior art keywords
telmiseartan
sodium salt
crystalline sodium
angiotensin antagonist
angiotensin
Prior art date
Application number
NO20041758A
Other languages
Norwegian (no)
Other versions
NO326465B1 (en
Inventor
Kai Donsbach
Irmagard Hof
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7704331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20041758(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20041758L publication Critical patent/NO20041758L/en
Publication of NO326465B1 publication Critical patent/NO326465B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20041758A 2001-10-31 2004-04-29 Crystalline sodium salt of Telmiseartan, process for the preparation of such, pharmaceutical formulations containing them and its use as a drug NO326465B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10153737A DE10153737A1 (en) 2001-10-31 2001-10-31 Crystalline sodium salt of telmisartan, process for its preparation and its use for the manufacture of a medicament
PCT/EP2002/011394 WO2003037876A1 (en) 2001-10-31 2002-10-11 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist

Publications (2)

Publication Number Publication Date
NO20041758L true NO20041758L (en) 2004-04-29
NO326465B1 NO326465B1 (en) 2008-12-08

Family

ID=7704331

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041758A NO326465B1 (en) 2001-10-31 2004-04-29 Crystalline sodium salt of Telmiseartan, process for the preparation of such, pharmaceutical formulations containing them and its use as a drug

Country Status (34)

Country Link
EP (1) EP1442023B1 (en)
JP (1) JP5124076B2 (en)
KR (1) KR100929502B1 (en)
CN (1) CN100509789C (en)
AR (1) AR037148A1 (en)
AT (1) ATE370125T1 (en)
AU (1) AU2002338886B2 (en)
BR (1) BR0213568A (en)
CA (1) CA2463146C (en)
CO (1) CO5580785A2 (en)
CY (1) CY1107504T1 (en)
DE (2) DE10153737A1 (en)
DK (1) DK1442023T3 (en)
EA (1) EA007596B1 (en)
EC (1) ECSP045089A (en)
ES (1) ES2291505T3 (en)
HR (1) HRPK20040372B4 (en)
HU (1) HUP0402391A3 (en)
IL (2) IL161165A0 (en)
ME (1) MEP43608A (en)
MX (1) MXPA04004013A (en)
MY (1) MY129741A (en)
NO (1) NO326465B1 (en)
NZ (1) NZ532716A (en)
PE (1) PE20030629A1 (en)
PL (1) PL211462B1 (en)
PT (1) PT1442023E (en)
RS (1) RS50879B (en)
SA (1) SA02230419B1 (en)
SI (1) SI1442023T1 (en)
TW (2) TWI341200B (en)
UA (1) UA82833C2 (en)
UY (1) UY27520A1 (en)
WO (1) WO2003037876A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
DE10319450A1 (en) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt
EP1713795A2 (en) 2004-02-11 2006-10-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
CN1953973A (en) * 2004-05-05 2007-04-25 特瓦制药工业有限公司 Preparation of candesartan cilexetil in high purity
WO2006044754A2 (en) 2004-10-18 2006-04-27 Dr. Reddy's Laboratories Ltd. Process for preparing telmisartan
MX2007005348A (en) * 2004-11-03 2007-06-25 Teva Pharma Amorphous and polymorphic forms of telmisartan sodium.
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2151450A1 (en) * 2008-07-29 2010-02-10 Sandoz AG Method for processing microbiologically produced cyclic oligopeptides
MX346039B (en) 2009-05-20 2017-03-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical oral telmisartan solution.
WO2011002425A2 (en) 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
EP2448576A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EA025946B1 (en) 2010-10-27 2017-02-28 Крка, Товарна Здравил, Д. Д., Ново Место Multilayer pharmaceutical composition comprising telmisartan and amlodipine
CN105503867B (en) 2011-11-25 2019-01-11 阿德弗里奥药品有限责任公司 The method for being used to prepare the fluoro- 1H- pyrazolo-pyridines of substituted 5-
CR20170146A (en) 2014-10-21 2017-08-10 Ariad Pharma Inc CRYSTAL FORMS OF 5-CHLORINE-N4 - [- 2- (DIMETHYLPHOSPHORIL) PHENYL] -N2- {2-METOXI-4- [4- (4-METHYLIPIPERAZIN-1-YL) PIPERIDIN-1-IL] PYRIMIDINE-2, 4-DIAMINE
KR101872726B1 (en) * 2016-07-28 2018-06-29 주식회사 씨트리 Telmisartan methanesulfonate and pharmaceutical composition comprising the same
SI3648761T1 (en) 2017-07-07 2024-07-31 Boehringer Ingelheim Vetmedica Gmbh Telmisartan for the prophylaxis or treatment of hypertension in cats
US20220098197A1 (en) * 2019-01-10 2022-03-31 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Salts of heterocyclic compound and use thereof
CN121175053A (en) 2023-05-24 2025-12-19 勃林格殷格翰动物保健有限公司 Combination treatment and/or prevention of kidney disease and/or hypertension in a non-human mammal comprising one or more SGLT-2 inhibitors and telmisartan
TW202508593A (en) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
WO2025125409A1 (en) 2023-12-15 2025-06-19 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
SI9210098B (en) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
JP4369994B2 (en) * 1996-02-29 2009-11-25 ノバルティス アクチエンゲゼルシャフト AT for lowering apoptosis 1 Receptor antagonist
DE19901921C2 (en) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphs of telmisartan, process for their preparation and their use in the manufacture of a medicament

Also Published As

Publication number Publication date
JP2005536445A (en) 2005-12-02
CA2463146A1 (en) 2003-05-08
TWI333419B (en) 2010-11-21
DE10153737A1 (en) 2003-05-28
EP1442023A1 (en) 2004-08-04
HK1073841A1 (en) 2005-10-21
CN1578772A (en) 2005-02-09
CO5580785A2 (en) 2005-11-30
JP5124076B2 (en) 2013-01-23
HRP20040372A8 (en) 2025-09-12
BR0213568A (en) 2004-09-08
TW201034664A (en) 2010-10-01
MXPA04004013A (en) 2004-06-18
WO2003037876A1 (en) 2003-05-08
TWI341200B (en) 2011-05-01
RS50879B (en) 2010-08-31
KR20050035172A (en) 2005-04-15
CY1107504T1 (en) 2013-03-13
PT1442023E (en) 2007-09-17
ES2291505T3 (en) 2008-03-01
EP1442023B1 (en) 2007-08-15
MEP43608A (en) 2011-02-10
MY129741A (en) 2007-04-30
NZ532716A (en) 2007-06-29
ECSP045089A (en) 2004-06-28
SI1442023T1 (en) 2007-12-31
YU36304A (en) 2006-08-17
DK1442023T3 (en) 2007-11-05
IL161165A0 (en) 2004-08-31
EA200400479A1 (en) 2004-10-28
NO326465B1 (en) 2008-12-08
CA2463146C (en) 2011-01-25
PL211462B1 (en) 2012-05-31
AU2002338886B2 (en) 2008-04-17
HRP20040372A2 (en) 2004-10-31
CN100509789C (en) 2009-07-08
HUP0402391A2 (en) 2005-03-29
SA02230419B1 (en) 2007-07-31
EA007596B1 (en) 2006-12-29
PE20030629A1 (en) 2003-07-14
KR100929502B1 (en) 2009-12-03
HRPK20040372B3 (en) 2006-02-28
HRPK20040372B4 (en) 2025-09-12
ATE370125T1 (en) 2007-09-15
HUP0402391A3 (en) 2010-03-29
UA82833C2 (en) 2008-05-26
PL367477A1 (en) 2005-02-21
AR037148A1 (en) 2004-10-27
TW200300082A (en) 2003-05-16
DE50210719D1 (en) 2007-09-27
IL161165A (en) 2009-12-24
UY27520A1 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
NO20041758L (en) Crystalline sodium salt of telmiseartan and its use as angiotensin antagonist
ATE258918T1 (en) CRYSTAL FORM ALPHA OF PERINDOPRIL-TERT-BUTYLAMINE SALT
DK1478629T3 (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterial agents
IS2529B (en) New spirotycyclic derivatives and their use as phosphodiesterase-7 inhibitors
DE60303751D1 (en) Real-time monitoring of formation fracture
IS7792A (en) Hydantoin derivatives and their use as TACE inhibitors
NO20026010L (en) Substituted quinazoline derivatives and their use as inhibitors
NO20043158L (en) Substituted quinazoline derivatives as inhibitors of aurorakinases
NO20005265L (en) Substituted benzamides, their preparation and use as inhibitors of cystine proteases
PL376575A1 (en) Substituted heterocyclic compounds and methods of use
NO20042719L (en) Substituted 2-amino-cycloalkanecarboxamides and their use as protease inhibitors
FI20021262A7 (en) Crystallization of sugars
AU2002338886A1 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
ATE391502T1 (en) CRYSTALLINE FORMS OF FLUVASTATIN SODIUM
DK1622612T3 (en) Pharmaceutical formulation of the sodium salt of telmitarsan
PT1432685E (en) CRYSTALLINE HYDRATES OF NICOTHINIC ACID AND BENZOYLENYLIDAN ANILIDA DERIVATIVES
DK1581518T3 (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
IL164698A0 (en) Attenuation of metapneumovirus
NO20041968L (en) Use of cystationin
PL373163A1 (en) Salt of (s)-pantoprazole and its hydrates
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
EP1558276A4 (en) FUSION INHIBITORS OF FLAVIVIRUS
FI20021531A0 (en) Procedure for masonry
SI1408964T1 (en) USE OF 2- 5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL?æ-CHROMANE AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS
EE200300567A (en) Method for the preparation of amorphous cilastatin sodium

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees